Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
52 studies found for:    physical | urticaria
Show Display Options
RSS Create an RSS feed from your search for:
physical | urticaria
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Pathogenesis of Physical Induced Urticarial Syndromes
Conditions: Autoinflammatory Syndromes;   Physical Urticaria
Intervention:
2 Recruiting Cold Urticaria Treatment With Xolair
Condition: Cold Contact Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
3 Completed Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
Condition: Urticaria
Interventions: Drug: Bilastine;   Drug: Levocetirizine;   Drug: Placebo
4 Completed
Has Results
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Drug: Omalizumab 75-375 mg;   Drug: Placebo to omalizumab;   Drug: Loratadine;   Drug: Clemastine
5 Completed
Has Results
Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)
Conditions: Rhinitis, Allergic, Seasonal;   Rhinitis, Allergic, Perennial;   Urticaria
Intervention: Drug: Desloratadine Syrup
6 Completed
Has Results
Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Condition: Idiopathic Solar Urticaria
Interventions: Drug: Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209);   Drug: Ti02 pigmentary 3% alone (formula RV3131A-MV1211);   Drug: bisoctrizole 10% alone (formula RV3131A-MV1237);   Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213);   Drug: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329);   Drug: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212);   Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)];   Drug: V0096 CR vehicle (formula RV3131A-MV1197)
7 Active, not recruiting A Long-Term Examination of Asthma From Childhood Through Adolescence
Conditions: Asthma;   Dermatitis, Atopic;   Rhinitis;   Urticaria
Intervention:
8 Completed
Has Results
Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: IGE025;   Drug: placebo
9 Completed An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)
Condition: Urticaria
Intervention: Drug: Desloratadine
10 Completed Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria
Condition: Urticaria
Interventions: Drug: Cetirizine;   Drug: Desloratadine;   Drug: Fexofenadine;   Drug: Ebastine;   Drug: Bilastine
11 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
12 Terminated Efficacy of Rupatadine 5, 10 and 20 Mg in Chronic Idiopathic Urticaria
Condition: Urticaria
Intervention: Drug: RUPATADINE (ANTI-HISTAMINE)
13 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Interventions: Drug: brentuximab vedotin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
14 Recruiting Urticaria Facticia Treatment With Omalizumab (UFO)
Condition: Symptomatic Dermographism
Interventions: Drug: Omalizumab;   Drug: Placebo
15 Completed Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
Conditions: Urticaria;   Vasculitis
Intervention: Drug: canakinumab
16 Recruiting The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire
Condition: Chronic Urticaria
Intervention: Other: CU-Q2oL
17 Recruiting Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test
Condition: Chronic Urticaria
Intervention: Other: Urticaria Control Test
18 Completed Bilastine Updosing - Characterization of Underlying Mechanisms
Condition: Cold Contact Urticaria
Intervention: Drug: Bilastine
19 Terminated Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions
Conditions: Atopic Dermatitis;   Psoriasis;   Alopecia;   Mycosis Fungoides;   Urticaria;   Dermatoses;   Stretch Marks
Intervention: Procedure: UVA1 and UVB Irradiation
20 Recruiting OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients
Condition: Chonic Spontaneous Urticaria
Intervention: Drug: omalizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years